{"entity":{"id":"medicare-negotiation-2028-cancer-drugs","kind":"term","name":"Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib","aka":["IPAY 2028","third cycle of Medicare drug price negotiation","Erleada negotiation","Kisqali negotiation","Verzenio negotiation","Lenvima negotiation"],"tldr":"Four cancer medicines are among the drugs selected for the third round of Medicare price negotiation, with prices due from 1 January 2028: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The negotiated prices had not been published in CMS's data file by November 2026.","summary":"United States, Medicare Drug Price Negotiation Program, third cycle. CMS's data file of 2 November 2026 lists fourteen drugs for initial price applicability year 2028, each with an effective date of 1 January 2028. Four are cancer medicines: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The file gives no maximum fair price for any 2028 drug yet; the price columns are blank.","asOf":"2026-11-04","links":[{"label":"CMS: Negotiation Program selected drug list and maximum fair price data file, 2 November 2026 (ZIP)","url":"https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip"},{"label":"CMS: Medicare Drug Price Negotiation Program","url":"https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program"}],"tags":["law","us"],"related":["medicare-negotiation-2026-cancer-drug","medicare-negotiation-2027-cancer-drugs"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["apalutamide","ribociclib","abemaciclib","lenvatinib"],"companies":[],"institutions":[],"pathways":[],"terms":["inflation-reduction-act"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The census counted 15 drugs for 2028 from a CMS fact sheet; the data file of 2 November 2026 lists 14. The record states what the file shows.","No 2028 price was in the file on 4 November 2026; none is stated."],"category":"Regulation & policy"},"route":"/terms/medicare-negotiation-2028-cancer-drugs/","neighbours":{"term":[{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"medicare-negotiation-2026-cancer-drug","kind":"term","name":"Medicare negotiated price for ibrutinib (Imbruvica), first cycle","route":"/terms/medicare-negotiation-2026-cancer-drug/"},{"id":"medicare-negotiation-2027-cancer-drugs","kind":"term","name":"Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib","route":"/terms/medicare-negotiation-2027-cancer-drugs/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}